Merck looks to ditch the needles with its next-gen oral PCSK9 inhibitor for high cholesterol
After winning approval about six years ago, the first wave of PCSK9 inhibitors largely failed to muster the blockbuster sales analysts had predicted. Now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
